Tretinoin (All-Trans Retinoic Acid) (Vesanoid) — Clinical FAQs

Question 1

What is Tretinoin (All-Trans Retinoic Acid) FDA-approved to treat?

Accepted Answer

Tretinoin (All-Trans Retinoic Acid) is FDA-approved for the following oncology indications: 1. Induction of remission in adults with APL (FAB M3) characterized by t(15;17) translocation and/or PML-RARα gene expression — used in combination with arsenic trioxide for low/intermediate-risk APL, or with anthracycline-based chemotherapy for high-risk APL (FDA approved 1995).

Question 2

How does Tretinoin (All-Trans Retinoic Acid) work (mechanism of action)?

Accepted Answer

Tretinoin (all-trans retinoic acid; ATRA) is a biologically active vitamin A derivative that directly targets the PML-RARα fusion oncoprotein driving acute promyelocytic leukemia (APL). The t(15;17) translocation generates PML-RARα, which recruits co-repressor complexes (NCoR, SMRT, HDAC) to RARα target gene promoters, arresting myeloid differentiation at the promyelocytic stage. At pharmacologic concentrations, ATRA binds the ligand-binding domain of the RARα moiety, inducing a conformational shift that dissociates co-repressors and recruits co-activators (CBP/p300, SRC family), derepressing genes required for terminal granulocytic differentiation and driving maturation of leukemic promyelocytes into non-proliferating granulocytes. ATRA also promotes proteasomal degradation of PML-RARα via SUMOylation and caspase cleavage — a mechanism complementary to arsenic trioxide, which targets the PML moiety, explaining the synergy of the ATO + ATRA combination.

Question 3

How is Tretinoin (All-Trans Retinoic Acid) administered?

Accepted Answer

Tretinoin (All-Trans Retinoic Acid) is administered Oral (PO). Administer 45 mg/m²/day orally in two equally divided doses (22.

Question 4

What are the most common side effects of Tretinoin (All-Trans Retinoic Acid)?

Accepted Answer

The most commonly reported side effects of Tretinoin (All-Trans Retinoic Acid) (≥10% incidence) include: Headache (86%) — often severe; may indicate pseudotumor cerebri, Fever (83%), Skin and mucous membrane dryness (77%) — cheilitis, xerosis, epistaxis, Bone pain (77%), Nausea and vomiting (57%) and others (18 total). Consult your oncologist for complete prescribing information.

Question 5

Does Tretinoin (All-Trans Retinoic Acid) have a black box warning?

Accepted Answer

Yes. Tretinoin (All-Trans Retinoic Acid) carries FDA black box warning(s) regarding: 1. APL differentiation syndrome (formerly ATRA syndrome): Tretinoin can cause a potentially fatal syndrome characterized by fever, dyspnea, acute respiratory distress, pulmonary infiltrates or consolidation, pericardial or pleural effusions, hypotension, and rapid weight gain (≥5 kg). Onset typically occurs within the first month of therapy. At the first suspicion of differentiation syndrome, immediately initiate dexamethasone 10 mg IV every 12 hours and continue for at least 3 days or until complete resolution. Temporarily interrupt tretinoin if severe respiratory compromise is present. Prompt recognition is lifesaving — do not delay corticosteroids pending diagnostic confirmation. 2. Teratogenicity — Pregnancy Category D: Tretinoin causes severe fetal malformations including craniofacial, cardiovascular, thymic, and limb defects. It must not be administered to pregnant women. Reliable non-hormonal contraception is mandatory for ALL patients of reproductive potential — both female patients and male patients with female partners — during therapy and for at least one month after discontinuation. Two negative pregnancy tests must be obtained before initiation in females of childbearing potential.

Question 6

Is Tretinoin (All-Trans Retinoic Acid) safe during pregnancy?

Accepted Answer

Tretinoin (All-Trans Retinoic Acid) pregnancy safety: Category D — causes severe fetal harm. Tretinoin is a potent human teratogen causing craniofacial, cardiovascular, thymic, and limb malformations. Absolutely contraindicated in pregnancy. All patients of reproductive potential — female AND male with female partners — must use two forms of effective non-hormonal contraception during therapy and for at least one month after the last dose. Two negative pregnancy tests are required before initiation in females of reproductive potential; monthly pregnancy testing continues throughout therapy.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Tretinoin (All-Trans Retinoic Acid) — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms